Neurogene Statistics

Total Valuation

Neurogene has a market cap or net worth of $242.60 million. The enterprise value is -$37.73 million.

Market Cap	242.60M
Enterprise Value	-37.73M

Important Dates

The last earnings date was Friday, May 9, 2025, before market open.

Earnings Date	May 9, 2025
Ex-Dividend Date	n/a

Share Statistics

Neurogene has 14.26 million shares outstanding. The number of shares has increased by 111.87% in one year.

Current Share Class	14.26M
Shares Outstanding	14.26M
Shares Change (YoY)	+111.87%
Shares Change (QoQ)	+7.84%
Owned by Insiders (%)	11.76%
Owned by Institutions (%)	52.26%
Float	3.23M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	262.88
Forward PS	n/a
PB Ratio	0.96
P/TBV Ratio	0.83
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 21.03, with a Debt / Equity ratio of 0.04.

Current Ratio	21.03
Quick Ratio	20.80
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-8,157.82

Financial Efficiency

Return on equity (ROE) is -34.97% and return on invested capital (ROIC) is -22.95%.

Return on Equity (ROE)	-34.97%
Return on Assets (ROA)	-21.97%
Return on Invested Capital (ROIC)	-22.95%
Return on Capital Employed (ROCE)	-29.79%
Revenue Per Employee	$8,645
Profits Per Employee	-$755,794
Employee Count	107
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -47.68% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-47.68%
50-Day Moving Average	14.18
200-Day Moving Average	26.48
Relative Strength Index (RSI)	53.65
Average Volume (20 Days)	215,148

Short Selling Information

The latest short interest is 2.70 million, so 18.90% of the outstanding shares have been sold short.

Short Interest	2.70M
Short Previous Month	2.95M
Short % of Shares Out	18.90%
Short % of Float	83.41%
Short Ratio (days to cover)	11.21

Income Statement

In the last 12 months, Neurogene had revenue of $925,000 and -$80.87 million in losses. Loss per share was -$4.35.

Revenue	925,000
Gross Profit	-64.20M
Operating Income	-89.74M
Pretax Income	-55.44M
Net Income	-80.87M
EBITDA	-86.55M
EBIT	-89.74M
Loss Per Share	-$4.35

Full Income Statement

Balance Sheet

The company has $292.60 million in cash and $11.71 million in debt, giving a net cash position of $280.90 million or $19.70 per share.

Cash & Cash Equivalents	292.60M
Total Debt	11.71M
Net Cash	280.90M
Net Cash Per Share	$19.70
Equity (Book Value)	291.80M
Book Value Per Share	19.54
Working Capital	282.30M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$69.73 million and capital expenditures -$1.52 million, giving a free cash flow of -$71.25 million.

Operating Cash Flow	-69.73M
Capital Expenditures	-1.52M
Free Cash Flow	-71.25M
FCF Per Share	-$5.00

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-9,701.19%
Pretax Margin	-8,742.70%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Neurogene does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-111.87%
Shareholder Yield	-111.87%
Earnings Yield	-33.26%
FCF Yield	-29.30%

Analyst Forecast

The average price target for Neurogene is $39.83, which is 134.16% higher than the current price. The consensus rating is "Buy".

Price Target	$39.83
Price Target Difference	134.16%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	127.54%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Neurogene has an Altman Z-Score of 10.01 and a Piotroski F-Score of 2.

Altman Z-Score	10.01
Piotroski F-Score	2